DUALITYBIO-B (09606) saw its shares rise more than 4% during the morning trading session. At the time of writing, the stock was up 2.42%, trading at HKD 363.6, with a turnover of HKD 51.06 million. On January 19, the company announced that its self-developed ADAM9-targeting antibody-drug conjugate (ADC), DB-1317, had received approval for clinical trials from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration. The approval permits the initiation of clinical trials for DB-1317 as a monotherapy in patients with advanced/metastatic malignant solid tumors. Reportedly, DB-1317 is a next-generation ADC product developed by DUALITYBIO based on its proprietary DITAC ADC technology platform and holds global rights. The target, ADAM9, is highly expressed in various cancers such as gastric cancer, colorectal cancer, pancreatic cancer, and non-small cell lung cancer, while its expression levels are low in normal tissues. Preclinical studies have demonstrated that DB-1317 exhibits significant anti-tumor activity across multiple tumor models.